Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$3.86 USD
+0.31 (8.73%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Summit Therapeutics PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -614.93 | -78.78 | -88.60 | -52.70 | -29.13 |
Depreciation/Amortization & Depletion | 2.05 | 2.51 | 2.46 | 2.00 | 1.64 |
Net Change from Assets/Liabilities | -6.54 | 0.18 | 5.95 | 5.00 | 2.01 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 542.65 | 34.51 | 7.61 | -2.42 | 4.72 |
Net Cash From Operating Activities | -76.76 | -41.58 | -72.59 | -48.11 | -20.76 |
Property & Equipment | 0.10 | -0.62 | -0.31 | -0.42 | -0.21 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -112.86 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | -475.02 | 0.00 | 0.00 | 0.00 | -0.14 |
Net Cash from Investing Activities | -587.77 | -0.62 | -0.31 | -0.42 | -0.34 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 111.82 | 100.40 | 78.09 | 50.60 | 50.42 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -24.69 | 520.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.62 | -0.16 | -0.17 | -0.05 | -0.91 |
Net Cash from Financing Activities | 86.51 | 620.24 | 77.92 | 50.55 | 49.51 |
Effect of Exchange Rate Changes | 0.84 | -1.22 | 0.35 | 0.56 | 0.19 |
Net Change In Cash & Equivalents | -577.18 | 576.82 | 5.37 | 2.58 | 28.60 |
Cash at Beginning of Period | 648.61 | 71.79 | 66.42 | 63.84 | 35.25 |
Cash at End of Period | 71.43 | 648.61 | 71.79 | 66.42 | 63.84 |
Diluted Net EPS | -0.99 | -0.41 | -0.96 | -0.76 | NA |
Fiscal Year End for Summit Therapeutics PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -614.93 | -578.36 | -557.09 | -542.38 |
Depreciation/Amortization & Depletion | NA | 2.05 | 1.45 | 0.85 | 0.38 |
Net Change from Assets/Liabilities | NA | -6.54 | -15.03 | -15.02 | -1.38 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 542.65 | 534.65 | 528.86 | 530.25 |
Net Cash From Operating Activities | NA | -76.76 | -57.30 | -42.40 | -13.13 |
Property & Equipment | NA | 0.10 | 0.10 | 0.15 | -0.05 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -112.86 | -173.43 | -169.99 | -170.00 |
Other Investing Activities | NA | -475.02 | -475.02 | -475.02 | -475.02 |
Net Cash from Investing Activities | NA | -587.77 | -648.34 | -644.86 | -645.06 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 111.82 | 105.57 | 105.34 | 104.69 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | -24.69 | -24.69 | -24.69 | -24.69 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.62 | -0.62 | -0.62 | 0.11 |
Net Cash from Financing Activities | NA | 86.51 | 80.26 | 80.03 | 80.11 |
Effect of Exchange Rate Changes | NA | 0.84 | 0.57 | 0.74 | 0.44 |
Net Change In Cash & Equivalents | NA | -577.18 | -624.82 | -606.49 | -577.64 |
Cash at Beginning of Period | NA | 648.61 | 648.61 | 648.61 | 648.61 |
Cash at End of Period | NA | 71.43 | 23.79 | 42.12 | 70.97 |
Diluted Net EPS | NA | 0.49 | -0.03 | -0.02 | -1.43 |